Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › camrelizumab

camrelizumab

14 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of camrelizumab

2 trials tracked of camrelizumab: 1 in phase 3 or 4 and 1 with published results. The most-cited published study has 594 citations.

2Trials tracked
1Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 3 1 Phase 2 1
  1. Phase 3 Study of SHR-1210 Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal Cancer Completed · 594 cited
  2. Phase 2 Neoadjuvant PD-1 Blockade in Resectable Oral Squamous Cell Carcinoma Completed

Showing the 2 most-cited and recently-updated of 2 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
SBRT plus PD-1 inhibitor and lenvatinib improved PFS in oligoprogressive HCC patients
Gastroenterology Phase II
SBRT plus PD-1 inhibitor and lenvatinib improved PFS in oligoprogressive HCC patients Radiation Plus Immune Drugs Stops Liver Cancer Growth
This prospective Phase 2 study evaluated stereotactic body radiation therapy (SBRT) combined with continued first-line PD-1 inhibitor-based …
Combining targeted radiation with ongoing immune therapy can restart cancer control in patients whose disease was slowly spreading again.
Apr 12, 2026
Guideline reviews perioperative immunotherapy for hepatocellular carcinoma after resection or ablation
Rheumatology Guideline
Guideline reviews perioperative immunotherapy for hepatocellular carcinoma after resection or ablation A New Strategy Emerges to Stop Liver Cancer From Coming Back
A guideline reviews perioperative immunotherapy for hepatocellular carcinoma after resection or ablation.
Doctors are finding smarter ways to use the body’s own immune system around the time of surgery to give patients with liver cancer a better …
Frontiers Apr 10, 2026